Recent share price weakness makes for a buying opportunity on Correvio Pharma (Correvio Pharma News, Stock Quote, Chart TSX, NASDAQ:CORV), says Mackie … [Read more...] about Correvio Pharma has tonnes of upside, says Mackie Research
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Bellus Health gets new $4.10 price target at Mackie Research Capital
Recent shifts in the competitive landscape have Mackie Research Capital analyst André Uddin raising his price target on Bellus Health (Bellus Health … [Read more...] about Bellus Health gets new $4.10 price target at Mackie Research Capital
Medexus is Canada’s best specialty pharma stock, Mackie Research says
Following the company's fourth quarter results, Mackie Research Capital analyst André Uddin is describing Medexus Pharmaceuticals (Medexus … [Read more...] about Medexus is Canada’s best specialty pharma stock, Mackie Research says
Sernova Corporation has an upside of 317 per cent, Echelon says
Impressive interim outcome data from Sernova Corporation (Sernova Corporation News, Stock Quote, Chart TSXV:SVA) has Echelon Wealth Partners analyst … [Read more...] about Sernova Corporation has an upside of 317 per cent, Echelon says
Time to hop on board Acasti Pharma, says Mackie Research
With its best-in-class omega-3 drug CaPre currently in Phase III trials, Acasti Pharma (Acasti Pharma News, Stock Quote, Chart TSXV:ACST) is ready for … [Read more...] about Time to hop on board Acasti Pharma, says Mackie Research
Medicenna Therapeutics has a 110 per cent upside, says Mackie Research
Investors should be thinking about clinical-stage biotech company Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart TSX:MDNA), … [Read more...] about Medicenna Therapeutics has a 110 per cent upside, says Mackie Research
Antibe Therapeutics has loads of upside, says Echelon Wealth
Echelon Wealth Partners analyst Douglas Loe is staying bullish on clinical stage drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, … [Read more...] about Antibe Therapeutics has loads of upside, says Echelon Wealth
Keep the faith with Knight Therapeutics, this analyst says
Patience is a virtue, especially when it comes to specialty pharma name Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD), which … [Read more...] about Keep the faith with Knight Therapeutics, this analyst says
Oncolytics Biotech has huge potential, says Echelon Wealth
Echelon Wealth Partners analyst Douglas Loe says price softness in cancer biologics developer Oncolytics Biotech (Oncolytics Biotech Stock Quote, … [Read more...] about Oncolytics Biotech has huge potential, says Echelon Wealth
Acasti Pharma has a 113 per cent upside, says Echelon Wealth
Echelon Wealth Partners analyst Douglas Loe is staying put on drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart TSXV:ACST) after the … [Read more...] about Acasti Pharma has a 113 per cent upside, says Echelon Wealth
